|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash and Cash Equivalents | ||||||||||||||||||||
| Accounts Receivable, net of allowance for credit losses of $46,000 at June 30, 2026 and December 31, 2025. | ||||||||||||||||||||
| Accrued Revenues in Excess of Billings | ||||||||||||||||||||
| Utility Improvement Refund/Employee Retention Credit Receivable | ||||||||||||||||||||
| Utility Improvement Refund | ||||||||||||||||||||
| Other Receivables | ||||||||||||||||||||
| Inventories, Net | ||||||||||||||||||||
| Manufacturing Vendor Prepayments | ||||||||||||||||||||
| Prepaid Expenses and Other Assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Long-Term Assets | ||||||||||||||||||||
| Fixed Assets, Net | ||||||||||||||||||||
| Operating Lease Right-of-Use Assets, Net | ||||||||||||||||||||
| Patents and Trademarks, Net | ||||||||||||||||||||
| Technology Licenses, Net | ||||||||||||||||||||
| Intangible Asset, Net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Cost Method Investment in Atomistic | ||||||||||||||||||||
| Other Assets, Net | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts Payable | ||||||||||||||||||||
| Unearned Revenue | ||||||||||||||||||||
| Accrued Expenses | ||||||||||||||||||||
| Licensing Fees Commitment | ||||||||||||||||||||
| Other Taxes Payable | ||||||||||||||||||||
| Operating Lease Right-of-Use Liabilities | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-Term Liabilities | ||||||||||||||||||||
| Operating Lease Right-of-Use Liabilities | ||||||||||||||||||||
| Total Long-Term Liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Preferred Stock - $0.001 Par Value, 5,000,000 Shares Authorized; 419,959 Shares of Series B Preferred Stock Issued and Outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Total preferred Stock - $0.001 Par Value, 5,000,000 Shares Authorized; 419,959 Shares of Series B Preferred Stock Issued and Outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Stockholders' Equity | ||||||||||||||||||||
| Common Stock - $0.001 Par Value, 200,000,000 shares authorized; 84,993,902 shares issued and 84,414,230 shares outstanding as of June 30, 2026 and 81,679,367 shares issued and 81,099,695 shares outstanding as of December 31, 2025 | ||||||||||||||||||||
| Additional Paid-in Capital | ||||||||||||||||||||
| Accumulated Deficit | ||||||||||||||||||||
| Treasury Stock, at cost, 579,672 shares as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities, Mezzanine Equity, and Stockholders' Equity | ||||||||||||||||||||
Loading...
